Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.34 +3.34 (+17.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss
Apellis Pharmaceuticals (APLS) reported mixed Q2 2025 results, missing revenue estimates ($178.49M vs. $192.29M) but beating EPS (-$0.33 vs. -$0.49). Shares rose 4.58% pre-market as FDA approval for... 
Via Chartmill
Earnings Scheduled For July 31, 2025
 
Via Benzinga
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria and clearing C3 deposits. 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Apellis Pharmaceuticals's Earnings Outlook
 
Via Benzinga
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Apellis Pharmaceuticals
 
Via Benzinga
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 
Via Stocktwits
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
 
Via Benzinga
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
 
Via Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
 
Via Benzinga
Why Apellis Pharmaceuticals Wilted on Wednesday
Via The Motley Fool
Topics Earnings
Analyst Expectations For Apellis Pharmaceuticals's Future
 
Via Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings)
 
Via Benzinga
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
 
Via Benzinga
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
 
Via Benzinga
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025. 
Via Benzinga
Earnings Scheduled For February 28, 2025
 
Via Benzinga
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations. 
Via The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
The company is best known for its drug, Syfovre, a treatment for geographic atrophy. 
Via Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.